U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H26O2
Molecular Weight 298.4192
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NORETHINDRONE

SMILES

[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]3([H])[C@@]4([H])CCC(=O)C=C4CC[C@@]23[H]

InChI

InChIKey=VIKNJXKGJWUCNN-XGXHKTLJSA-N
InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1

HIDE SMILES / InChI
Molecular Formula C20H26O2
Molecular Weight 298.4192
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:09:50 UTC 2023
Edited
by admin
on Fri Dec 15 15:09:50 UTC 2023
Record UNII
T18F433X4S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NORETHINDRONE
HSDB   MI   ORANGE BOOK   USP   USP-RS   VANDF  
Common Name English
FEMCON FE COMPONENT NORETHINDRONE
Common Name English
NORETHINDRONE [USP IMPURITY]
Common Name English
NORETHISTERONUM [WHO-IP LATIN]
Common Name English
UTOVLAN
Common Name English
NORQUEST FE COMPONENT NORETHINDRONE
Common Name English
Norethisterone [WHO-DD]
Common Name English
NOR-QD
Brand Name English
NORETHINDRONE COMPONENT OF FEMCON FE
Common Name English
VYFEMLA COMPONENT NORETHINDRONE
Brand Name English
NORETHINDRONE [MI]
Common Name English
NORETHISTERONE [MART.]
Common Name English
NORETHISTERONE ACETATE IMPURITY A [EP IMPURITY]
Common Name English
NORETHISTERONE [EP IMPURITY]
Common Name English
NORETHISTERONE
EP   INN   MART.   WHO-DD   WHO-IP  
INN  
Official Name English
SC-4640
Code English
CAMILA
Brand Name English
17-Hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one
Common Name English
NORETHISTERON
Common Name English
NSC-9564
Code English
NORETHINDRONE [HSDB]
Common Name English
19-NORPREGN-4-EN-20-YN-3-ONE, 17-HYDROXY-, (17.ALPHA.)-
Common Name English
LO MINASTRIN FE COMPONENT NORETHINDRONE
Brand Name English
NORETHINDRONE COMPONENT OF NORQUEST FE
Common Name English
MICRONOR
Brand Name English
TAYTULLA COMPONENT NORETHINDRONE
Brand Name English
TRIELLA
Common Name English
BREVICON COMPONENT NORETHINDRONE
Brand Name English
NORETHINDRONE [VANDF]
Common Name English
ARANELLE COMPONENT NORETHINDRONE
Common Name English
NORLUTIN
Brand Name English
NORETHINDRONE COMPONENT OF ARANELLE
Common Name English
ANOVULE
Common Name English
NORETHINDRONE [ORANGE BOOK]
Common Name English
norethisterone [INN]
Common Name English
NORETHINDRONE [USP MONOGRAPH]
Common Name English
NORETHINDRONE [USP-RS]
Common Name English
NORINYL COMPONENT NORETHINDRONE
Brand Name English
MINASTRIN 24 FE COMPONENT NORETHINDRONE
Brand Name English
GESTEST
Common Name English
NORETHISTERONE [JAN]
Common Name English
NORETHISTERONE [WHO-IP]
Common Name English
LEVONORGESTREL IMPURITY U [EP IMPURITY]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175602
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 18.3.1 (ETH/NOR)
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
NCI_THESAURUS C776
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
LIVERTOX 696
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
WHO-VATC QG03AA05
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
WHO-VATC QG03AC01
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
NDF-RT N0000011301
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
WHO-ATC G03AC01
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
WHO-VATC QG03FA01
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
WHO-ATC G03FA01
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
WHO-VATC QG03AB04
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
WHO-ATC G03FB05
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
WHO-VATC QG03DC02
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
WHO-ATC G03DC02
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
WHO-VATC QG03FB05
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
WHO-ATC G03AA05
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
WHO-ATC G03AB04
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
Code System Code Type Description
NSC
9564
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
EVMPD
SUB09362MIG
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
IUPHAR
2880
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
NORETHINDRONE
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY Description: A white or creamy white, crystalline powder; odourless. Solubility: Practically insoluble in water; soluble in 150 parts of ethanol (~750 g/l) TS and in 80 parts of acetone R. Category: Progestational steroid. Storage: Norethisterone should be kept in a well-closed container, protected from light.Definition: Norethisterone contains not less than 97.0% and not more than 103.0% of C20H26O2, calculated with reference to thedried substance.
PUBCHEM
6230
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
DAILYMED
T18F433X4S
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
DRUG CENTRAL
1962
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
RS_ITEM_NUM
1469005
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
HSDB
3370
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
EVMPD
SUB87911
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
FDA UNII
T18F433X4S
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
MESH
D009640
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
RXCUI
7514
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY RxNorm
SMS_ID
100000092090
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
NCI_THESAURUS
C62059
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
ChEMBL
CHEMBL1162
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
MERCK INDEX
m8056
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY Merck Index
ECHA (EC/EINECS)
200-681-6
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
INN
687
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
EPA CompTox
DTXSID9023380
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
DRUG BANK
DB00717
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
LACTMED
Norethindrone
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
CAS
68-22-4
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
WIKIPEDIA
NORETHISTERONE
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
CHEBI
7627
Created by admin on Fri Dec 15 15:09:50 UTC 2023 , Edited by admin on Fri Dec 15 15:09:50 UTC 2023
PRIMARY
Related Record Type Details
Structure of 3.ALPHA.,5.ALPHA.-TETRAHYDRONORETHISTERONE
METABOLITE LESS ACTIVE -> PARENT
Relative Binding Affinity (RBA) to Human Progesterone receptor (cytosol of human breast MCF-7 cells); Unit: % (relative to Org-2058 (=100%)); Norethindrone was 21.5%
IN-VITRO
Structure of 17.ALPHA.-ETHYNYL-5.BETA.-ESTRANE-3.ALPHA.,17.BETA.-DIOL-3-SULFATE
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 1mg (w/50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
PLASMA
Structure of NORETHYNODREL
PARENT -> METABOLITE
Metabolite to parent drug ratio in non-uraemic human plasma. Norethynodrel is metabolized in man to the antifertility agent norethisterone(norethindrone).
METABOLITE TO PARENT DRUG RATIO
PLASMA; URINE
Structure of 17.BETA.-HYDROXY-17.ALPHA.-ETHYNYL-5.BETA.-ESTRAN-3-ONE
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 25mg single oral administration (one woman); blood was obtained 3hr after ingestion
IN-VIVO
PLASMA
Structure of 17.ALPHA.-ETHYNYL-5.BETA.-ESTRANE-3.ALPHA.,17.BETA.-DIOL
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 25mg single oral administration (one woman); blood was obtained 3hr after ingestion
IN-VIVO
PLASMA
Structure of 17.ALPHA.-ETHYNYL-5.BETA.-ESTRANE-3.ALPHA.,17.BETA.-DIOL-3-GLUCURONIDE
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 3hr after 25mg single oral administration
IN-VIVO
PLASMA
Structure of 17.ALPHA.-ETHYNYL-5.ALPHA.-ESTRANE-3.ALPHA.,17.BETA.-DIOL-3-GLUCURONIDE
METABOLITE INACTIVE -> PARENT
IN-VIVO
PLASMA
Structure of 17.ALPHA.-ETHYNYL-5.ALPHA.-ESTRANE-3.ALPHA.,17.BETA.-DIOL-3-SULFATE
METABOLITE INACTIVE -> PARENT
Unit: ng/mL (expressed as a mixture of the 3- (predominant) and 17-sulfate); 1mg (w/50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
PLASMA
Structure of 3.ALPHA.,5.ALPHA.-TETRAHYDRONORETHISTERONE
METABOLITE LESS ACTIVE -> PARENT
Unit: ng/ml; 25mg single oral administration (one female); blood was obtained 3hr after the oral ingestion
IN-VIVO
PLASMA
Structure of NORETHINDRONE GLUCURONIDE
METABOLITE INACTIVE -> PARENT
unit: ng/mL; 25mg single oral administration; blood sampled after 3hr
IN-VIVO
PLASMA
Structure of 17.BETA.-HYDROXY-17.ALPHA.-ETHYNYL-5.BETA.-ESTRAN-3-ONE
METABOLITE INACTIVE -> PARENT
IN-VIVO
PLASMA
Structure of 17.ALPHA.-ETHYNYL-5.ALPHA.-ESTRANE-3.ALPHA.,17.BETA.-DIOL DISULFATE
METABOLITE INACTIVE -> PARENT
Unit: mcg/24hr; 1mg (w/50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
URINE
Structure of 17.ALPHA.-ETHYNYL-5.BETA.-ESTRANE-3.BETA.,17.BETA.-DIOL-3-SULFATE
METABOLITE INACTIVE -> PARENT
IN-VIVO
PLASMA
Structure of NORETHINDRONE GLUCURONIDE
METABOLITE INACTIVE -> PARENT
unit: mcg/24h; 1mg q.d. oral administration (w/50mcg estranol); blood sampled on the 7th, 14th, and 21st days (two females)
IN-VIVO
URINE
Structure of 17.ALPHA.-ETHYNYL-5.BETA.-ESTRANE-3.BETA.,17.BETA.-DIOL
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 25mg single oral administration (one woman); blood was obtained 3hr after ingestion
IN-VIVO
PLASMA
Structure of 3.ALPHA.,5.ALPHA.-TETRAHYDRONORETHISTERONE
METABOLITE LESS ACTIVE -> PARENT
Trace amount; Unit: mcg in a urine pool (2.5% aliquot from each of 4days of urine); 25mg q.d. oral administration (one woman)
IN-VIVO
URINE
Structure of 17.ALPHA.-ETHYNYL-5.ALPHA.-ESTRANE-3.BETA.,17.BETA.-DIOL-3-SULFATE
METABOLITE INACTIVE -> PARENT
IN-VIVO
PLASMA
Structure of 17.ALPHA.-ETHYNYL-5.BETA.-ESTRANE-3.BETA.,17.BETA.-DIOL
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 2mg (w/0.1mg mestranol) q.d. oral administration; blood was taken 3hr after the tenth pill ingestion on day 14 of the cycle (one woman)
IN-VIVO
PLASMA
Structure of 17.ALPHA.-ETHYNYL-5.ALPHA.-ESTRANE-3.ALPHA.,17.BETA.-DIOL-3-GLUCURONIDE
METABOLITE INACTIVE -> PARENT
Unit: mcg/24hr; 1mg (w/50mgg mestranol) q.d. oral administration sampled on the 7th, 14th, and 21st days (two females)
IN-VIVO
URINE
Structure of 17.ALPHA.-ETHYNYL-5.BETA.-ESTRANE-3.ALPHA.,17.BETA.-DIOL-17-SULFATE
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of 17.ALPHA.-ETHYNYL-5.BETA.-ESTRANE-3.BETA.,17.BETA.-DIOL-3-SULFATE
METABOLITE INACTIVE -> PARENT
Unit: mcg/24hr; 1mg (w/50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
URINE
Structure of 17.ALPHA.-ETHYNYL-5.BETA.-ESTRANE-3.BETA.,17.BETA.-DIOL DISULFATE
METABOLITE INACTIVE -> PARENT
<2 to 12; Unit: ng/mL; 1mg (50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
PLASMA
Structure of 17.ALPHA.-ETHYNYL-5.ALPHA.-ESTRANE-3.BETA.,17.BETA.-DIOL-3-GLUCURONIDE
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of 17.ALPHA.-ETHYNYL-5.ALPHA.-ESTRANE-3.ALPHA.,17.BETA.-DIOL DISULFATE
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 1mg (w/50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
PLASMA
Structure of 17.ALPHA.-ETHYNYL-5.BETA.-ESTRANE-3.ALPHA.,17.BETA.-DIOL DISULFATE
METABOLITE INACTIVE -> PARENT
Unit: mcg/24hr; 1mg (w/50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
URINE
Structure of 17.ALPHA.-ETHYNYL-5.BETA.-ESTRANE-3.ALPHA.,17.BETA.-DIOL-3-SULFATE
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of NORETHINDRONE SULFATE
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 1mg (w/50mcg mestranol) q.d. oral administration sampled on the 7th, 14th, and 21st days (two females)
IN-VIVO
PLASMA
Structure of 17.ALPHA.-ETHYNYL-5.BETA.-ESTRANE-3.BETA.,17.BETA.-DIOL DISULFATE
METABOLITE INACTIVE -> PARENT
<2; Unit: mcg/24hr; 1mg (50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
URINE
Structure of 17.ALPHA.-ETHYNYL-5.BETA.-ESTRANE-3.ALPHA.,17.BETA.-DIOL
METABOLITE INACTIVE -> PARENT
Unit: mcg in pooled urine (2.5% aliquot from each of the 4 days urine); 25mg q.d. oral administration for 4 days (one woman)
IN-VIVO
URINE
Structure of NORETHINDRONE SULFATE
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 1mg (w/50mcg mestranol) q.d. oral administration sampled on the 7th, 14th, and 21st days (two females)
IN-VIVO
URINE
Structure of 17.ALPHA.-ETHYNYL-5.BETA.-ESTRANE-3.ALPHA.,17.BETA.-DIOL
METABOLITE INACTIVE -> PARENT
Unit: ng/ml; 2mg (w/0.1mg mestranol) q.d. oral administration (one woman); blood was taken 3hr after ingestion of the tenth pill on day 14 of the cycle
IN-VIVO
PLASMA
Structure of 17.ALPHA.-ETHYNYL-5.BETA.-ESTRANE-3.BETA.,17.BETA.-DIOL-3-GLUCURONIDE
METABOLITE INACTIVE -> PARENT
Unit: mcg in a urine pool (2.5% aliquot from each of 4 days of urine); 25mg q.d. oral administration for 4 days
IN-VIVO
URINE
Structure of 3.ALPHA.,5.ALPHA.-TETRAHYDRONORETHISTERONE
METABOLITE LESS ACTIVE -> PARENT
Unit: ng/mL; 2mg (w/0.1mg mestranol) q.d. oral administration; blood was obtained 3hr after the tenth pill administration on day 14 of the cycle
IN-VIVO
PLASMA
Structure of 17.ALPHA.-ETHYNYL-5.ALPHA.-ESTRANE-3.BETA.,17.BETA.-DIOL DISULFATE
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 1mg (50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
PLASMA
Structure of 17.ALPHA.-ETHYNYL-5.BETA.-ESTRANE-3.ALPHA.,17.BETA.-DIOL DISULFATE
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 1mg (w/50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
PLASMA
Structure of 17.ALPHA.-ETHYNYL-5.ALPHA.-ESTRANE-3.ALPHA.,17.BETA.-DIOL-3-SULFATE
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of 17.ALPHA.-ETHYNYL-5.BETA.-ESTRANE-3.ALPHA.,17.BETA.-DIOL-3-GLUCURONIDE
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of 17.ALPHA.-ETHYNYL-5.ALPHA.-ESTRANE-3.BETA.,17.BETA.-DIOL DISULFATE
METABOLITE INACTIVE -> PARENT
<2; Unit: mcg/24hr; 1mg (50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
URINE
Related Record Type Details
Structure of 3-ETHYNYL-19-NOR-17.ALPHA.-PREGNA-3,5-DIEN-20-YN-17-OL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of LEVONORGESTREL
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 18-METHYLLEVONORGESTREL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of NORETHINDRONE ACETATE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of NORETHYNODREL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of NORETHINDRONE 3-ETHYL ETHER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6,7-DEHYDRONORETHINDRONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6.BETA.-HYDROXYNORETHINDRONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of DELTA-5(6)-DIDEHYDRONORETHINDRONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 19-NORANDROSTENEDIONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of NORETHINDRONE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Structure of NORETHINDRONE
Elimination
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Structure of NORETHINDRONE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966